Zydus Wellness

Impact in US among the worst in the past 10 years

According to the technical analyst from Anand Rathi, Godfreh Phillips can jump to Rs 1,320, while Zydus Wellness can be bought for a target of Rs 1,860.

Zydus Wellness reported a 4.75 per cent rise in consolidated net profit to Rs 137.01 crore in the first quarter ended June 30, impacted by higher expenses and a one-time outgo for plant closure

Zydus Lifesciences on Thursday said the US health regulator has issued three observations after inspecting its Jarod (Vadodara) based manufacturing facility. The US Food and Drug Administration (USFDA) inspected the injectable facility from February 24 to March 10, 2022. The inspection closed with three observations, the drug firm said in a regulatory filing. "We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated. As per the US health regulator, an FDA Form 483 (observation) is issued to a firm's management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of Food Drug and Cosmetic (FD&C) Act and related Act.

The company reported consolidated net sales of Rs 384.9 crore, a growth of 2.3%; Five key brands maintained leadership positions in respective categories

Mirakle is more effective than oral vitamin C capsules and the absorption rate of nutrients in the drink is 98 per cent

FMCG firm Zydus Wellness is expecting to continue its growth momentum gathered post easing of lockdown and grow the business on the back of new launches

All that happened in the markets today

The company is also planning to enter new markets with relevant offering as part of expanding its geographical footprint, Zydus Wellness said

Zydus group firm Zydus Wellness on Friday reported a 10.94 per cent rise in consolidated net profit at Rs 89.20 crore for the quarter ended June 30, 2020. The company had posted a net profit of Rs 80.40 crore for the corresponding period of the previous year,Zydus Wellness said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 537.37 crore for the quarter under consideration, as against Rs 620.25 crore in the year-ago period, it added. The past quarter was an "unprecedented one" due to the COVID-19 pandemic impacting the company's operations in the early part of the quarter, Zydus Wellness said. "However, with the logistical challenges being resolved and approvals for re-starting manufacturing plants and operating C&FA warehouses coming in, the company was able to recover from the early setbacks,"it added. Coping with the pandemic, the company continues to be agile in its responses and execution of its plans,Zydus Wellness said. Shares of Zydus .

According to Zydus Wellness, the Covid-19 pandemic and the subsequent lockdown disrupted the supply chain and virtually no sales were reported in the later part of March 2020.

Over a year since the company acquired Complan, Glucon-D and Nycil, it is redrawing the marketing formula around its newly acquired brands

To become part of the consumer's monthly shopping cart, Sugar Free has launched new formats and variants and waged war against online venom

The company's total consolidated income from operations rose 333 per cent to Rs 620 crore from Rs 152 crore in Q1FY19

Consumer business crucial for Cadila Healthcare, at a time when US and India have pricing pressure

Heinz India, a subsidiary of the US-based Kraft Heinz, has now ceased to exist after the amalgamation of the two subsdiaries

In October 2018, Zydus Wellness had announced acquisition of Heinz India's consumer wellness business

Analysts expect acquisition to be earnings accretive in around 3 years

This is the first time a private equity player will be on Zydus' board of directors

At 10:06 am, the stock was trading at Rs 1,287.80, up 2.54 per cent from the previous close. A total of 12,672 shares exchanged hands on the counter.